This small-cap pharma stock, engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets, rose over 2% in today’s trade after receiving approval for its product globally.
With the market capitalisation of Rs 11,259 Crores, the shares of Marksans Pharma ltd has reached an intraday high of Rs. 256 per equity share, rising nearly 2.4 percent from its previous day’s close price of Rs. 250.15. Since then, the stock has retreated and is currently trading at Rs. 245.50 per equity share.
Marksans Pharma ltd focused on the formulation and marketing of generic pharmaceutical products across regulated markets, jumped over 2 percent after its UK-based wholly owned subsidiary, Relonchem Limited, received Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for its product Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution. The approval marks a significant step in expanding its footprint in the UK healthcare market.
Marksans Pharma is at the forefront of the pharmaceutical industry, distinguished by a customer-centric approach. Specializing in Over-the-Counter (OTC) and prescription drugs.
The company has cultivated a strong presence in highly regulated markets.Leveraging robust Research and Development (R&D) capabilities and advanced manufacturing facilities both domestically and internationally, and they are among the top five Indian Companies in the United Kingdom.
Marksans Pharma’s strategic emphasis on optimizing supply chain efficiencies has facilitated substantial business expansion across key global markets. Its high-quality and expansive portfolio has led to a growing foothold in the USA as well.
Looking forward to the company’s financial performance, revenue increased by 20.5 percent from Rs 2177 crore in FY24 to Rs 2623 crore in FY25. Further, during the same time frame, net profit increased by 21.5 percent from Rs 315 crore to Rs 383 crore.
In FY25, the company reported robust geographic revenue performance, with the US & North America leading at Rs 1,237 crore, reflecting a strong 35% year-on-year growth.
The UK & Europe followed with Rs 1,030 crore, up 9% YoY. Australia & New Zealand contributed Rs 253 crore, up by 16% YoY. The Rest of the World (RoW) segment added RS 104 crore, registering a 6% YoY increase. LINK
Written By: Rohan Pandey
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
